tiprankstipranks
Hims & Hers Health (MX:HIMS)
:HIMS
Mexico Market
HIMS
Hims & Hers Health
RESEARCH TOOLSreports

Hims & Hers Health (HIMS) Stock Forecast & Price Target

0 Followers
See the Price Targets and Ratings of:

HIMS Analyst Ratings

Hold
14Ratings
Hold
3 Buy
11 Hold
0 Sell
Based on 14 analysts giving stock ratings to
Hims
& Hers Health
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

HIMS Stock 12 Month Forecast

Average Price Target

$562.55
▲(11.82% Upside)
Based on 14 Wall Street analysts offering 12 month price targets for Hims & Hers Health in the last 3 months. The average price target is $562.55 with a high forecast of $719.94 and a low forecast of $445.68. The average price target represents a 11.82% change from the last price of $503.10.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"284":"$284","1035":"$1,035","471.75":"$471.8","659.5":"$659.5","847.25":"$847.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":719.94240444,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$719.94</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":562.5523982745455,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$562.55</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":445.67863132,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$445.68</span>\n  </div></div>","useHTML":true}}],"tickPositions":[284,471.75,659.5,847.25,1035],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Dec<br/>2025","6":"Mar<br/>2026","9":"Jun<br/>2026","12":"Sep<br/>2026","25":"Sep<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,484,502.14941572615385,520.2988314523077,538.4482471784615,556.5976629046154,574.7470786307692,592.8964943569231,611.0459100830769,629.1953258092308,647.3447415353846,665.4941572615385,683.6435729876923,701.7929887138462,{"y":719.94240444,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,484,490.04249217496505,496.0849843499301,502.1274765248951,508.16996869986014,514.2124608748252,520.2549530497902,526.2974452247553,532.3399373997203,538.3824295746853,544.4249217496504,550.4674139246154,556.5099060995805,{"y":562.5523982745455,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,484,481.05220240923074,478.10440481846155,475.1566072276923,472.2088096369231,469.26101204615384,466.31321445538464,463.3654168646154,460.4176192738462,457.46982168307693,454.52202409230773,451.5742265015385,448.6264289107693,{"y":445.67863132,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":815,"date":1756684800000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 11</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":1034,"date":1759276800000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 13</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":841.79,"date":1761955200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 18</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":696.02,"date":1764547200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 15</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":581.43,"date":1767225600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 13</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":474,"date":1769904000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 20, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 12</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":285,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 31, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 9</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":355,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 36, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 6</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":474.92,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 32, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":482.66,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 21, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":650,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 25, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":480,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 22, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":484,"date":1788220800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 26, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$719.94Average Price Target$562.55Lowest Price Target$445.68
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Bank of America Securities Analyst forecast on MX:HIMS
Allen Lutz
Bank of America Securities
Bank of America Securities
$548.53
Hold
9.03%
Upside
Reiterated
09/15/26
Bank of America Securities Sticks to Its Hold Rating for Hims & Hers Health (HIMS)
J.P. Morgan Analyst forecast on MX:HIMS
Bryan Smilek
J.P. Morgan
J.P. Morgan
$548.53
Hold
9.03%
Upside
Initiated
09/11/26
Hims & Hers assumed with a Neutral at JPMorganHims & Hers assumed with a Neutral at JPMorgan
Truist Financial Analyst forecast on MX:HIMS
Jailendra Singh
Truist Financial
Truist Financial
$548.53
Hold
9.03%
Upside
Reiterated
09/11/26
Analysts' Opinions Are Mixed on These Healthcare Stocks: TransMedics Group (NASDAQ: TMDX) and Hims & Hers Health (NYSE: HIMS)
Jefferies Analyst forecast on MX:HIMS
Brian Tanquilut
Jefferies
Jefferies
$531.39
Hold
5.62%
Upside
Reiterated
09/03/26
Analysts Conflicted on These Healthcare Names: ClearPoint Neuro (NASDAQ: CLPT), Hims & Hers Health (NYSE: HIMS) and Phreesia (NYSE: PHR)
KeyBanc Analyst forecast on MX:HIMS
Justin Patterson
KeyBanc
KeyBanc
―
Hold
―
Reiterated
09/02/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: Hims & Hers Health (NYSE: HIMS) and Oxford BioMedica (Other OTC: OXBDF)
Barclays Analyst forecast on MX:HIMS
Glen Santangelo
Barclays
Barclays
$668.52→$599.95
Buy
19.25%
Upside
Reiterated
08/20/26
Analysts Offer Insights on Healthcare Companies: Hims & Hers Health (NYSE: HIMS) and ProMIS Neurosciences (NASDAQ: PMN)
Citi Analyst forecast on MX:HIMS
Daniel Grosslight
Citi
Citi
$599.95→$565.67
Hold
12.44%
Upside
Reiterated
08/12/26
Hims & Hers price target lowered to $33 from $35 at CitiHims & Hers price target lowered to $33 from $35 at Citi
Evercore ISI Analyst forecast on MX:HIMS
Mark Mahaney
Evercore ISI
Evercore ISI
―
Hold
―
Reiterated
08/11/26
Analysts Conflicted on These Healthcare Names: Silence Therapeutics (NASDAQ: SLN), Hims & Hers Health (NYSE: HIMS) and Syndax Pharmaceuticals (NASDAQ: SNDX)
Canaccord Genuity Analyst forecast on MX:HIMS
Maria Ripps
Canaccord Genuity
Canaccord Genuity
$685.66
Buy
36.29%
Upside
Reiterated
08/11/26
Analysts Are Bullish on Top Healthcare Stocks: Hims & Hers Health (HIMS), TELA Bio (TELA)
Morgan Stanley Analyst forecast on MX:HIMS
Craig Hettenbach
Morgan Stanley
Morgan Stanley
$359.97→$479.96
Hold
-4.60%
Downside
Assigned
08/11/26
Hims & Hers price target raised to $28 from $21 at Morgan StanleyHims & Hers price target raised to $28 from $21 at Morgan Stanley
Deutsche Bank Analyst forecast on MX:HIMS
George Hill
Deutsche Bank
Deutsche Bank
$428.54→$445.68
Hold
-11.41%
Downside
Assigned
08/11/26
Hims & Hers price target raised to $26 from $25 at Deutsche BankHims & Hers price target raised to $26 from $25 at Deutsche Bank
TD Cowen Analyst forecast on MX:HIMS
Jonna Kim
TD Cowen
TD Cowen
$428.54→$514.24
Hold
2.22%
Upside
Assigned
08/11/26
Analysts Offer Insights on Healthcare Companies: Zentalis Pharmaceuticals (NASDAQ: ZNTL), Agilon Health (NYSE: AGL) and Hims & Hers Health (NYSE: HIMS)
BTIG Analyst forecast on MX:HIMS
David Larsen
BTIG
BTIG
―
Hold
―
Assigned
08/11/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: Hims & Hers Health (NYSE: HIMS), Merit Medical Systems (NASDAQ: MMSI) and Intuitive Surgical (NASDAQ: ISRG)
Needham Analyst forecast on MX:HIMS
Ryan MacDonald
Needham
Needham
$599.95→$719.94
Buy
43.10%
Upside
Reiterated
08/11/26
Hims & Hers: Strong GLP-1-Driven Momentum, Strategic AI & International Investments Underpin Buy Rating and Raised $42 Price Target
Leerink Partners Analyst forecast on MX:HIMS
Michael Cherny
Leerink Partners
Leerink Partners
―
Hold
―
Reiterated
04/16/26
Push to ease peptide restrictions positive for Hims & Hers, says Leerink Push to ease peptide restrictions positive for Hims & Hers, says Leerink
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Bank of America Securities Analyst forecast on MX:HIMS
Allen Lutz
Bank of America Securities
Bank of America Securities
$548.53
Hold
9.03%
Upside
Reiterated
09/15/26
Bank of America Securities Sticks to Its Hold Rating for Hims & Hers Health (HIMS)
J.P. Morgan Analyst forecast on MX:HIMS
Bryan Smilek
J.P. Morgan
J.P. Morgan
$548.53
Hold
9.03%
Upside
Initiated
09/11/26
Hims & Hers assumed with a Neutral at JPMorganHims & Hers assumed with a Neutral at JPMorgan
Truist Financial Analyst forecast on MX:HIMS
Jailendra Singh
Truist Financial
Truist Financial
$548.53
Hold
9.03%
Upside
Reiterated
09/11/26
Analysts' Opinions Are Mixed on These Healthcare Stocks: TransMedics Group (NASDAQ: TMDX) and Hims & Hers Health (NYSE: HIMS)
Jefferies Analyst forecast on MX:HIMS
Brian Tanquilut
Jefferies
Jefferies
$531.39
Hold
5.62%
Upside
Reiterated
09/03/26
Analysts Conflicted on These Healthcare Names: ClearPoint Neuro (NASDAQ: CLPT), Hims & Hers Health (NYSE: HIMS) and Phreesia (NYSE: PHR)
KeyBanc Analyst forecast on MX:HIMS
Justin Patterson
KeyBanc
KeyBanc
―
Hold
―
Reiterated
09/02/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: Hims & Hers Health (NYSE: HIMS) and Oxford BioMedica (Other OTC: OXBDF)
Barclays Analyst forecast on MX:HIMS
Glen Santangelo
Barclays
Barclays
$668.52→$599.95
Buy
19.25%
Upside
Reiterated
08/20/26
Analysts Offer Insights on Healthcare Companies: Hims & Hers Health (NYSE: HIMS) and ProMIS Neurosciences (NASDAQ: PMN)
Citi Analyst forecast on MX:HIMS
Daniel Grosslight
Citi
Citi
$599.95→$565.67
Hold
12.44%
Upside
Reiterated
08/12/26
Hims & Hers price target lowered to $33 from $35 at CitiHims & Hers price target lowered to $33 from $35 at Citi
Evercore ISI Analyst forecast on MX:HIMS
Mark Mahaney
Evercore ISI
Evercore ISI
―
Hold
―
Reiterated
08/11/26
Analysts Conflicted on These Healthcare Names: Silence Therapeutics (NASDAQ: SLN), Hims & Hers Health (NYSE: HIMS) and Syndax Pharmaceuticals (NASDAQ: SNDX)
Canaccord Genuity Analyst forecast on MX:HIMS
Maria Ripps
Canaccord Genuity
Canaccord Genuity
$685.66
Buy
36.29%
Upside
Reiterated
08/11/26
Analysts Are Bullish on Top Healthcare Stocks: Hims & Hers Health (HIMS), TELA Bio (TELA)
Morgan Stanley Analyst forecast on MX:HIMS
Craig Hettenbach
Morgan Stanley
Morgan Stanley
$359.97→$479.96
Hold
-4.60%
Downside
Assigned
08/11/26
Hims & Hers price target raised to $28 from $21 at Morgan StanleyHims & Hers price target raised to $28 from $21 at Morgan Stanley
Deutsche Bank Analyst forecast on MX:HIMS
George Hill
Deutsche Bank
Deutsche Bank
$428.54→$445.68
Hold
-11.41%
Downside
Assigned
08/11/26
Hims & Hers price target raised to $26 from $25 at Deutsche BankHims & Hers price target raised to $26 from $25 at Deutsche Bank
TD Cowen Analyst forecast on MX:HIMS
Jonna Kim
TD Cowen
TD Cowen
$428.54→$514.24
Hold
2.22%
Upside
Assigned
08/11/26
Analysts Offer Insights on Healthcare Companies: Zentalis Pharmaceuticals (NASDAQ: ZNTL), Agilon Health (NYSE: AGL) and Hims & Hers Health (NYSE: HIMS)
BTIG Analyst forecast on MX:HIMS
David Larsen
BTIG
BTIG
―
Hold
―
Assigned
08/11/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: Hims & Hers Health (NYSE: HIMS), Merit Medical Systems (NASDAQ: MMSI) and Intuitive Surgical (NASDAQ: ISRG)
Needham Analyst forecast on MX:HIMS
Ryan MacDonald
Needham
Needham
$599.95→$719.94
Buy
43.10%
Upside
Reiterated
08/11/26
Hims & Hers: Strong GLP-1-Driven Momentum, Strategic AI & International Investments Underpin Buy Rating and Raised $42 Price Target
Leerink Partners Analyst forecast on MX:HIMS
Michael Cherny
Leerink Partners
Leerink Partners
―
Hold
―
Reiterated
04/16/26
Push to ease peptide restrictions positive for Hims & Hers, says Leerink Push to ease peptide restrictions positive for Hims & Hers, says Leerink
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
PTGXProtagonist Therapeutics
ESTAEstablishment Labs Holdings
HITIHigh Tide
JAZZJazz Pharmaceuticals
OMCLOmnicell
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Hims & Hers Health

3 Months
Maria RippsCanaccord Genuity
Success Rate
11/16 ratings generated profit
69%
Average Return
+21.89%
Copying Maria Ripps's trades and holding each position for 3 Months would result in 68.75% of your transactions generating a profit, with an average return of +21.89% per trade.
1 Year
Glen SantangeloBarclays
Success Rate
8/13 ratings generated profit
62%
Average Return
+24.60%
Copying Glen Santangelo's trades and holding each position for 1 Year would result in 61.54% of your transactions generating a profit, with an average return of +24.60% per trade.
2 Years
Glen SantangeloBarclays
Success Rate
8/13 ratings generated profit
62%
Average Return
+25.48%
Copying Glen Santangelo's trades and holding each position for 2 Years would result in 61.54% of your transactions generating a profit, with an average return of +25.48% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

HIMS Analyst Recommendation Trends

Rating
May 26
Jun 26
Jul 26
Aug 26
Sep 26
Strong Buy
1
0
0
0
0
Buy
10
8
10
9
7
Hold
32
21
25
22
26
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
43
29
35
31
33
In the current month, HIMS has received 7 Buy Ratings, 26 Hold Ratings, and 0 Sell Ratings. HIMS average Analyst price target in the past 3 months is 562.55.
Each month's total comprises the sum of three months' worth of ratings.

HIMS Financial Forecast

HIMS Earnings Forecast

Next quarter’s earnings estimate for HIMS is $0.97 with a range of -$0.85 to $3.40. The previous quarter’s EPS was -$6.29. HIMS beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year HIMS has Performed in-line its overall industry.
Next quarter’s earnings estimate for HIMS is $0.97 with a range of -$0.85 to $3.40. The previous quarter’s EPS was -$6.29. HIMS beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year HIMS has Performed in-line its overall industry.

HIMS Sales Forecast

Next quarter’s sales forecast for HIMS is $15.17B with a range of $15.02B to $15.32B. The previous quarter’s sales results were $12.80B. HIMS beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year HIMS has Performed in-line its overall industry.
Next quarter’s sales forecast for HIMS is $15.17B with a range of $15.02B to $15.32B. The previous quarter’s sales results were $12.80B. HIMS beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year HIMS has Performed in-line its overall industry.

HIMS Stock Forecast FAQ

What is MX:HIMS’s average 12-month price target, according to analysts?
Based on analyst ratings, Hims & Hers Health’s 12-month average price target is 562.55.
    What is MX:HIMS’s upside potential, based on the analysts’ average price target?
    Hims & Hers Health has 11.82% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is Hims & Hers Health a Buy, Sell or Hold?
          Hims & Hers Health has a consensus rating of Hold, which is based on 3 buy ratings, 11 hold ratings and 0 sell ratings.
            What is Hims & Hers Health’s share price target?
            The average share price target for Hims & Hers Health is 562.55. This is based on 14 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst share price target is $719.94 ,and the lowest forecast is $445.68. The average share price target represents 11.82% Increase from the current price of $503.1.
              What do analysts say about Hims & Hers Health?
              Hims & Hers Health’s analyst rating consensus is a Hold. This is based on the ratings of 14 Wall Streets Analysts.
                How can I buy shares of Hims & Hers Health?
                To buy shares of MX:HIMS, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.